Key result
Enalapril orodispersible minitablets achieve 100% acceptability in young children with heart failure.
Why the study?
Enalapril is foundational in pediatric heart failure but is often given off-label to young children using extemporaneous formulations, motivating evaluation of the acceptability and palatability of an age-appropriate enalapril orodispersible minitablet (ODMT).
Are novel enalapril orodispersible minitablets acceptable and palatable in children up to 6 years of age with heart failure?
Are novel enalapril orodispersible minitablets acceptable and palatable in children up to 6 years of age with heart failure?
This study provides the first clinical evidence that an active-ingredient enalapril orodispersible minitablet is 100% acceptable and 96% palatable in neonates, infants, and young children with heart failure, offering a stable, age-appropriate alternative to unlicensed extemporaneous liquid or crushed-tablet preparations.
Answers are grounded in this paper and cite their sources.
May facilitate enalapril use in young children with heart failure; leaves open randomized confirmation of outcomes.
Background: Angiotensin-converting enzyme inhibitors, such as enalapril, are foundational in treating pediatric heart failure. However, they are often administered off-label to young children using extemporaneous formulations. This study, conducted as part of the EU-funded Labeling of Enalapril from Neonates up to Adolescents (LENA) project, aimed to evaluate the acceptability and palatability of an age-appropriate enalapril orodispersible minitablet (ODMT). These factors are critical for ensuring adherence, efficacy, and safety in pediatric patients. Methods: An 8-week trial was conducted in children with heart failure caused by dilated cardiomyopathy or congenital heart disease. Enalapril ODMTs (0.25 mg or 1.0 mg) were dose-titrated and administered to 38 children aged 0–6 months and 22 children aged 6 months to 6 years. This study aimed to assess its acceptability and palatability, key factors contributing to adherence, and therefore, efficacy and safety. Results: Across all 169 assessments in 38 children aged 0–6 months and 22 aged 6 months to 6 years, complete or partial swallowability was observed, and the acceptability rate was 100%. There were no cases of choking, inhalation/coughing, or spitting out. A favorable or neutral rating was observed in 96% of palatability assessments based on observations of facial expressions. Acceptability and palatability were higher in subjects aged 6 months–6 years than 0–6 months, with no significant influence from repeated administration. Conclusions: Enalapril ODMTs are widely accepted and well-tolerated among young children, including neonates, with heart failure. These findings suggest that ODMTs are a suitable and effective method for administering pediatric medicinal products.
No takes yet. Share an insight, caveat, or question.
Lazić et al. (2025) studied Pediatric heart failure due to congenital heart disease or dilated cardiomyopathy (n=60). Enalapril orodispersible minitablet (ODMT) was evaluated on Acceptability (aggregate of 'everything swallowed' and 'chewed/partially swallowed' via oral inspection). Enalapril orodispersible minitablets achieved a 100% acceptability rate and 96% palatability rate across 169 assessments in children up to 6 years old with heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: